Portfolio Overview - Elme Communities owns approximately 9,400 apartment homes, with 75% located in the Washington Metro area and 25% in the Atlanta Metro area[18] - The company anticipates an operational upside of $2.4 million to $2.6 million in 2025[18] - 79% of the apartment portfolio is classified as B Value-Add, while 10% is Class B, 7% is Class A-, and 4% is Class A[18] Financial Performance and Guidance - Elme Communities projects Core FFO per diluted share to be between $0.91 and $0.97 in 2025[47] - Same-store multifamily revenue growth is expected to range from 2.1% to 3.6% in 2025[47] - Same-store multifamily NOI growth is projected to be between 1.5% and 3.5%[47] - Other same-store NOI, consisting of Watergate 600, is expected to range from $11.5 million to $12.25 million[47] Market Dynamics and Strategy - Elme submarkets are expected to have a lower annual net inventory growth of 2.1% compared to the US average of 2.9% and Sunbelt markets average of 3.8%[56,58] - The company targets Class B rents priced below 95% of the market median to minimize competition with new deliveries in both Washington and Atlanta metros[85,88] - Elme's renovation pipeline includes approximately 3,000 units, with an expected spend of ~$8.6 million in 2025 and an ROI of approximately 18% in Q1 2025[40,44]

Financial Performance - CONMED's Q1 2025 worldwide revenue reached $321.3 million[22] - The company's GAAP EPS was $0.19, a decrease of 69.3% year-over-year[22, 25] - Adjusted EPS was $0.95, an increase of 20.1% year-over-year[22, 25] - Single-use products accounted for 86% of worldwide revenue[24] - The company anticipates approximately 4% to 6% constant currency revenue growth for the full year 2025, projecting reported revenue between $1350 million and $1378 million[26] Segment Performance - Orthopedic surgery revenue was $138.3 million with 3.9% constant currency growth[22] - General surgery revenue was $183.0 million with 3.8% constant currency growth[22] - Domestic revenue accounted for 57% and international revenue accounted for 43% of the total revenue[22] - Domestic revenue grew 3.4% and international revenue grew 5.4% (3.8% in constant currency)[22] Market and Strategy - The orthopedics market is estimated to be between $5.1 billion and $5.3 billion[10] - The US capital equipment market within orthopedics represents 38% of the total, while international accounts for 62%[10] - The general surgery market includes segments like access ($1.5 to $1.7 billion), energy ($3.1 to $3.3 billion), and endoscopic technologies ($3.1 to $3.3 billion)[11] - The company aims to achieve above-market revenue and profitability growth over the long term[9]